Demographic characteristics of ALL survivors and participants in the 2003 BRFSS, 18-44 y old
| . | ALL survivors (N = 2,648), n (%) . | BRFSS (N = 110,623), n (%) . | P . | |||
|---|---|---|---|---|---|---|
| Age at interview, y | ||||||
| 18-24 | 788 (29.8) | 18,359 (16.6) | <0.001 | |||
| 25-34 | 1,375 (51.9) | 40,238 (36.4) | ||||
| 35-44 | 485 (18.3) | 52,026 (47.0) | ||||
| Sex | ||||||
| Male | 1,314 (49.6) | 44,945 (40.6) | <0.001 | |||
| Female | 1,334 (50.4) | 65,678 (59.4) | ||||
| Race/ethnicity | ||||||
| White, NH | 2,332 (88.4) | 122,803 (72.5) | <0.001 | |||
| Black, NH | 81 (3.1) | 14,582 (9.4) | ||||
| Other, NH | 87 (3.3) | 11,417 (7.6) | ||||
| Hispanic/Latino | 138 (5.2) | 14,807 (10.6) | ||||
| Household income (US$) | ||||||
| <20,000 | 321 (14.6) | 17,832 (17.9) | <0.001 | |||
| ≥20,000 | 1,875 (85.4) | 81,943 (82.1) | ||||
| Educational level | ||||||
| Did not graduate HS | 120 (4.6) | 9,639 (8.7) | <0.001 | |||
| Graduated from HS | 442 (16.8) | 31,939 (28.9) | ||||
| Some college or technical school | 1,061 (40.4) | 32,147 (29.1) | ||||
| Graduated from college or technical school | 1,003 (38.2) | 36,746 (33.3) | ||||
| Current smoker | ||||||
| Yes | 419 (15.9) | 28,676 (26.0) | <0.001 | |||
| No | 2,219 (84.1) | 81,773 (74.0) | ||||
| BMI categories | ||||||
| Neither overweight nor obese (<25 kg/m2) | 1,031 (40.6) | 44,171 (45.7) | <0.001 | |||
| Overweight (25 to <30 kg/m2) | 814 (32.1) | 34,875 (33.1) | ||||
| Obese (≥30 kg/m2) | 694 (27.3) | 22,450 (21.3) | ||||
| Cancer therapy | ||||||
| Chemotherapy (% yes)* | ||||||
| Cytarabine | 1,286 (53.0) | Not applicable | ||||
| Cyclophosphamide | 1,232 (50.8) | |||||
| Daunorubicin | 697 (28.7) | |||||
| Dexamethasone | 295 (12.2) | |||||
| Doxorubicin | 673 (27.8) | |||||
| Thioguanine | 365 (15.1) | |||||
| Etoposide | 198 (8.2) | |||||
| Anthracycline, any | ||||||
| None | 1,301 (55.0) | Not applicable | ||||
| <300 mg/m2 | 662 (28.0) | |||||
| ≥300 mg/m2 | 404 (17.0) | |||||
| CRT (Gy) | ||||||
| None | 810 (35.5) | Not applicable | ||||
| 10.0-19.9 | 695 (30.4) | |||||
| ≥20 | 778 (34.1) | |||||
| . | ALL survivors (N = 2,648), n (%) . | BRFSS (N = 110,623), n (%) . | P . | |||
|---|---|---|---|---|---|---|
| Age at interview, y | ||||||
| 18-24 | 788 (29.8) | 18,359 (16.6) | <0.001 | |||
| 25-34 | 1,375 (51.9) | 40,238 (36.4) | ||||
| 35-44 | 485 (18.3) | 52,026 (47.0) | ||||
| Sex | ||||||
| Male | 1,314 (49.6) | 44,945 (40.6) | <0.001 | |||
| Female | 1,334 (50.4) | 65,678 (59.4) | ||||
| Race/ethnicity | ||||||
| White, NH | 2,332 (88.4) | 122,803 (72.5) | <0.001 | |||
| Black, NH | 81 (3.1) | 14,582 (9.4) | ||||
| Other, NH | 87 (3.3) | 11,417 (7.6) | ||||
| Hispanic/Latino | 138 (5.2) | 14,807 (10.6) | ||||
| Household income (US$) | ||||||
| <20,000 | 321 (14.6) | 17,832 (17.9) | <0.001 | |||
| ≥20,000 | 1,875 (85.4) | 81,943 (82.1) | ||||
| Educational level | ||||||
| Did not graduate HS | 120 (4.6) | 9,639 (8.7) | <0.001 | |||
| Graduated from HS | 442 (16.8) | 31,939 (28.9) | ||||
| Some college or technical school | 1,061 (40.4) | 32,147 (29.1) | ||||
| Graduated from college or technical school | 1,003 (38.2) | 36,746 (33.3) | ||||
| Current smoker | ||||||
| Yes | 419 (15.9) | 28,676 (26.0) | <0.001 | |||
| No | 2,219 (84.1) | 81,773 (74.0) | ||||
| BMI categories | ||||||
| Neither overweight nor obese (<25 kg/m2) | 1,031 (40.6) | 44,171 (45.7) | <0.001 | |||
| Overweight (25 to <30 kg/m2) | 814 (32.1) | 34,875 (33.1) | ||||
| Obese (≥30 kg/m2) | 694 (27.3) | 22,450 (21.3) | ||||
| Cancer therapy | ||||||
| Chemotherapy (% yes)* | ||||||
| Cytarabine | 1,286 (53.0) | Not applicable | ||||
| Cyclophosphamide | 1,232 (50.8) | |||||
| Daunorubicin | 697 (28.7) | |||||
| Dexamethasone | 295 (12.2) | |||||
| Doxorubicin | 673 (27.8) | |||||
| Thioguanine | 365 (15.1) | |||||
| Etoposide | 198 (8.2) | |||||
| Anthracycline, any | ||||||
| None | 1,301 (55.0) | Not applicable | ||||
| <300 mg/m2 | 662 (28.0) | |||||
| ≥300 mg/m2 | 404 (17.0) | |||||
| CRT (Gy) | ||||||
| None | 810 (35.5) | Not applicable | ||||
| 10.0-19.9 | 695 (30.4) | |||||
| ≥20 | 778 (34.1) | |||||
NOTE: Percentage is based upon available data for each variable.
Abbreviations: NH, non-Hispanic; HS, high school; CRT, cranial radiation therapy.
Over 90% of survivors received the following chemotherapy agents: l-asparaginase, 6-mercaptopurine, methotrexate, prednisone, and vincristine.